2021 Revenues ($USD) : $3,385,302,000
2021 Revenues (foreign currencies) : €2,868,900,000
2021 R&D spend : $505,512,000
2021 Number of Employees : 5,700
Fiscal Year End : 12/31/2021
Leader : CEO David Loew

The mid-size biopharma Ipsen achieved 12.3% growth in 2021, with overall revenue hitting €2.87 billion. Its specialty care division had a growth rate of 12.7%. Key drugs in its portfolio include Somatuline (lanreotide) and Decapeptyl (triptorelin) in its specialty care segment and the diarrhea drug Smecta in its consumer healthcare segment. Core drug candidates in its pipeline include the combination of cabometyx and atezolizumab as a potential second-line therapy for non-small cell lung cancer and Onivyde, a potential second-line small cell lung cancer therapy. Ipsen has R&D hubs in Shanghai, Paris-Saclay in France; Oxford, U.K. and Cambridge, Massachusetts. —BB